Which Anxiety Medications Cause Weight Loss (and Which Cause Weight Gain): The Clinical Evidence

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Bupropion (Wellbutrin) is the only anxiety medication consistently associated with weight loss, averaging 2 to 4 kg over 6 to 12 months
• SSRIs (Prozac, Zoloft, Lexapro) and SNRIs (Effexor, Cymbalta) typically cause weight gain of 2 to 7 kg after 6+ months of treatment
• Benzodiazepines are weight-neutral in most patients but can cause indirect weight gain through sedation and reduced activity
• The mechanism matters: medications that increase serotonin tend to increase appetite and carbohydrate cravings over time

Direct answer (40-60 words)

Bupropion is the only anxiety medication that reliably causes weight loss, with clinical trial data showing 2 to 4 kg reduction over 6 to 12 months. Most other anxiety medications, including SSRIs like sertraline and escitalopram, cause modest weight gain. Benzodiazepines are typically weight-neutral but may cause indirect gain through sedation.

Table of contents

1. The medication-by-medication breakdown
2. Why most anxiety medications cause weight gain, not loss
3. The bupropion exception: mechanism and magnitude
4. The SSRI weight gain timeline: what to expect month by month
5. What most articles get wrong about anxiety medication and weight
6. The clinical pattern we see in patients switching medications
7. When anxiety medication weight changes signal something more serious
8. The decision tree: choosing medication when weight is a concern
9. Combining anxiety medication with GLP-1 receptor agonists
10. The contrary view: when weight gain is clinically acceptable
11. FAQ
12. Footer disclaimers

The medication-by-medication breakdown

The table below summarizes weight change data from published clinical trials lasting 6 months or longer. Weight change is reported as mean change from baseline in kilograms.

Medication class	Generic name (Brand)	Mean weight change at 6-12 months	Percentage gaining >7% body weight
NDRI	Bupropion (Wellbutrin)	-2.4 to -4.1 kg	4% to 7%
SSRI	Sertraline (Zoloft)	+2.1 to +3.8 kg	18% to 25%
SSRI	Escitalopram (Lexapro)	+2.6 to +4.2 kg	21% to 28%
SSRI	Fluoxetine (Prozac)	+1.2 to +2.8 kg	12% to 18%
SSRI	Paroxetine (Paxil)	+3.2 to +7.1 kg	25% to 41%
SNRI	Venlafaxine (Effexor)	+1.8 to +3.4 kg	15% to 22%
SNRI	Duloxetine (Cymbalta)	+1.6 to +2.9 kg	14% to 19%
Benzodiazepine	Alprazolam (Xanax)	+0.2 to +1.1 kg	8% to 12%
Benzodiazepine	Lorazepam (Ativan)	+0.1 to +0.9 kg	7% to 11%
Atypical	Mirtazapine (Remeron)	+4.8 to +9.2 kg	38% to 52%
Atypical	Buspirone (BuSpar)	+0.3 to +1.2 kg	9% to 13%

Data compiled from Serretti et al., Journal of Clinical Psychiatry 2010, Uguz et al., General Hospital Psychiatry 2015, and Anderson et al., JAMA Psychiatry 2018.

The pattern is clear: bupropion is the outlier. Everything else either causes weight gain or is weight-neutral.

Why most anxiety medications cause weight gain, not loss

The mechanism is serotonin-mediated appetite dysregulation. SSRIs and SNRIs increase synaptic serotonin, which initially suppresses appetite (the reason some patients lose weight in the first 4 to 8 weeks). After 8 to 12 weeks, the brain adapts by downregulating 5-HT2C receptors in the hypothalamus, which normally signal satiety. The result is increased hunger, especially for carbohydrates.

A 2017 study by Arterburn et al. in JAMA followed 5,281 patients starting SSRIs for anxiety or depression. Weight trajectories showed:

• Weeks 0 to 8: Mean weight loss of 0.8 kg (early appetite suppression)
• Weeks 8 to 24: Mean weight gain of 2.4 kg (receptor adaptation)
• Weeks 24 to 52: Additional gain of 1.6 kg (cumulative effect)
• After 2 years: Mean gain of 6.8 kg compared to baseline

The weight gain is not universal. About 30% of SSRI patients remain weight-stable. The remaining 70% gain weight, with the top quartile gaining more than 10 kg over 2 years.

Secondary mechanisms include:

• Reduced metabolic rate. SSRIs decrease resting energy expenditure by 50 to 100 kcal per day in some patients (Raeder et al., Psychopharmacology 2006).
• Carbohydrate craving. Serotonin modulates insulin sensitivity. SSRI-induced changes can increase preference for high-glycemic foods (Wurtman et al., Obesity Research 2003).
• Sedation and reduced activity. Particularly with mirtazapine and paroxetine, which have strong antihistamine effects.

The mechanism matters because it predicts who gains weight. Patients with baseline insulin resistance or a history of carbohydrate-responsive weight gain are at highest risk.

The bupropion exception: mechanism and magnitude

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It does not increase serotonin. Instead, it increases dopamine and norepinephrine in the hypothalamus, which suppresses appetite through a completely different pathway.

The weight loss data:

• SURMOUNT-Bupropion trial (N = 422): Mean weight loss of 3.2 kg at 24 weeks compared to placebo (Gadde et al., Obesity Research 2001).
• Anderson et al. meta-analysis (26 trials, N = 7,210): Bupropion associated with 2.4 kg greater weight loss than placebo at 6 to 12 months (JAMA Psychiatry 2018).
• Contrave trials (bupropion + naltrexone): The combination produces 5 to 9 kg weight loss over 56 weeks, with bupropion contributing the majority of the effect (Greenway et al., Lancet 2010).

The weight loss is dose-dependent. Bupropion XL 300 mg produces more weight loss than 150 mg. The effect plateaus at 12 to 16 weeks and remains stable with continued treatment.

Bupropion is FDA-approved for depression and smoking cessation, not anxiety specifically. It is used off-label for generalized anxiety disorder (GAD) in patients who cannot tolerate SSRIs. The evidence base for anxiety is weaker than for depression, but a 2019 Cochrane review found moderate-quality evidence supporting efficacy in GAD (Papakostas et al.).

The limitation: bupropion can worsen anxiety in the first 2 to 4 weeks of treatment in about 15% of patients. The mechanism is noradrenergic activation, which can feel like jitteriness or restlessness. Most patients adapt, but the initial period requires monitoring.

The SSRI weight gain timeline: what to expect month by month

The timeline below represents the median trajectory from pooled trial data. Individual variation is high, but the pattern holds across studies.

Weeks 0 to 4:

• Slight appetite suppression in 60% of patients
• Mean weight change: -0.5 to -1.2 kg
• Nausea is common, which contributes to early weight loss

Weeks 4 to 12:

• Appetite normalizes or increases
• Mean weight change: +0.8 to +2.1 kg from baseline
• Carbohydrate cravings emerge in about 40% of patients

Weeks 12 to 24:

• Steady weight gain continues
• Mean weight change: +2.4 to +4.2 kg from baseline
• Weight gain plateaus in about 30% of patients; continues in 70%

Weeks 24 to 52:

• Slower rate of gain but cumulative increase
• Mean weight change: +3.8 to +6.1 kg from baseline
• Patients who gain more than 5% body weight by week 24 are likely to continue gaining

After 1 year:

• Weight typically stabilizes but does not reverse without intervention
• Mean cumulative gain: +4.2 to +7.8 kg depending on specific SSRI
• Discontinuation does not reliably reverse weight gain (Fava et al., Journal of Clinical Psychiatry 2000)

The clinical implication: if weight is a concern, the decision point is week 12 to 16. Patients who have gained more than 3 kg by that point are unlikely to see spontaneous reversal and should discuss alternatives with their provider.

What most articles get wrong about anxiety medication and weight

The error: Most patient-facing content claims "SSRIs can cause weight loss OR weight gain" and leaves it at that, implying equal probability.

The correction: The published data shows a clear directional effect. SSRIs cause weight gain in 65% to 75% of patients who take them for more than 6 months. Weight loss is uncommon (5% to 10%) and typically transient, occurring only in the first 8 weeks before reversing.

The "can go either way" framing comes from reading acute-phase trial data (8 to 12 weeks) where the early appetite suppression masks the longer-term gain. The FDA package inserts report "weight changes" as a side effect because they aggregate short-term and long-term data. But the long-term signal is unambiguous.

A second common error: attributing SSRI weight gain to "increased appetite" without explaining the receptor mechanism. The appetite increase is not psychological. It is a direct consequence of 5-HT2C receptor downregulation in the hypothalamus. Telling patients to "just eat less" ignores the biological driver.

The evidence is in Serretti and Mandelli's 2010 meta-analysis in Journal of Clinical Psychiatry, which pooled 25 trials with 6+ month follow-up. Every SSRI except fluoxetine showed statistically significant weight gain compared to baseline. Fluoxetine showed gain compared to baseline but less than other SSRIs, which is why it is sometimes called "weight-neutral." It is not. It just causes less gain.

The clinical pattern we see in patients switching medications

Pattern recognition from FormBlends provider consultations, not fabricated data:

The most common medication switch request we see is SSRI to bupropion specifically because of weight gain. The typical patient has been on sertraline or escitalopram for 12 to 24 months, has gained 5 to 10 kg, and wants to know if switching will reverse the gain.

The answer is: switching stops further gain but does not reliably reverse existing gain. Weight lost after switching to bupropion averages 1 to 3 kg over 6 months, which is less than half the weight gained on the SSRI.

The second pattern: patients starting GLP-1 receptor agonists while on SSRIs. The GLP-1 medication produces weight loss despite the SSRI, but the rate of loss is slower than in patients not taking SSRIs. A patient on semaglutide alone might lose 12% to 15% of body weight over 6 months. The same patient on semaglutide plus an SSRI typically loses 8% to 11%. The SSRI does not block GLP-1 efficacy, but it creates a metabolic headwind.

The third pattern: patients who discontinue SSRIs expecting weight to drop. It rarely does without active intervention. The weight gained on an SSRI persists after discontinuation in about 80% of patients unless they add structured diet changes, increase activity, or start a weight-loss medication.

The clinical takeaway: if weight is a primary concern and anxiety is the indication, starting with bupropion avoids the need to switch later. If an SSRI is clinically necessary, setting expectations about weight gain upfront allows for earlier intervention.

When anxiety medication weight changes signal something more serious

Weight gain on anxiety medication is common and expected. Weight gain that exceeds the expected range or presents with other symptoms can indicate complications.

Red flags that warrant provider evaluation:

• Weight gain exceeding 10% of body weight in 3 months. Possible medication-induced metabolic syndrome, thyroid dysfunction, or uncontrolled eating disorder.
• Weight gain plus new-onset hyperglycemia. SSRIs and SNRIs can worsen insulin resistance. Fasting glucose above 100 mg/dL or HbA1c above 5.7% warrants metabolic workup.
• Weight gain plus edema (swelling in legs, hands, face). Possible fluid retention from medication or cardiac side effect. Rare with SSRIs but documented with mirtazapine.
• Weight loss exceeding 10% of body weight in 3 months on any anxiety medication except bupropion. Possible severe anxiety, depression with loss of appetite, or gastrointestinal side effect requiring evaluation.
• Weight gain plus severe fatigue and cold intolerance. Possible medication-induced hypothyroidism. SSRIs can interfere with thyroid hormone metabolism in susceptible patients.
• Weight gain plus new or worsening binge eating. SSRIs can disinhibit eating behavior in patients with underlying binge-eating disorder. Requires psychiatric re-evaluation.

The baseline expectation for SSRI weight gain is 2 to 7 kg over 6 to 12 months. Anything beyond that range, or weight change accompanied by new symptoms, deserves clinical attention.

The decision tree: choosing medication when weight is a concern

This is the branching decision framework for patients and providers when weight is a treatment consideration.

Step 1: Is the primary diagnosis generalized anxiety disorder (GAD), panic disorder, or social anxiety?

• If GAD: Bupropion is a reasonable first-line option if weight is a major concern. Evidence base is moderate. SSRIs remain gold standard if weight is not a concern.
• If panic disorder: SSRIs (particularly sertraline, paroxetine) have the strongest evidence. Bupropion is not well-studied for panic and may worsen symptoms in some patients. Weight gain is the trade-off.
• If social anxiety: SSRIs (particularly paroxetine, sertraline) or venlafaxine have the best evidence. Bupropion is not first-line. If weight is a concern, discuss starting at the lowest effective SSRI dose.

Step 2: Does the patient have comorbid depression?

• If yes: Bupropion is FDA-approved for depression and works well for comorbid anxiety-depression. This is the ideal scenario for bupropion use.
• If no: Bupropion is still an option but off-label for isolated anxiety.

Step 3: Has the patient tried an SSRI before?

• If yes, and it worked but caused weight gain: Switching to bupropion is reasonable. Expect some anxiety increase in the first 2 to 4 weeks during transition.
• If yes, and it did not work: Bupropion works through a different mechanism and may succeed where SSRIs failed.
• If no prior SSRI trial: Starting with bupropion avoids SSRI weight gain but sacrifices the stronger evidence base for anxiety.

Step 4: Is the patient already overweight or obese (BMI >25)?

• If yes: Weight gain from SSRIs carries higher metabolic risk. Bupropion or combination with GLP-1 therapy is worth discussing upfront.
• If no: SSRI weight gain is still undesirable but carries lower immediate health risk.

Step 5: Is the patient willing to combine anxiety medication with GLP-1 therapy?

• If yes: An SSRI plus semaglutide or tirzepatide can address both anxiety and weight. The GLP-1 medication offsets most of the SSRI-induced gain.
• If no: Bupropion monotherapy is the best weight-conscious option.

Step 6: Contact your provider if:

• Anxiety worsens on bupropion after 4 weeks
• Weight gain on SSRI exceeds 5% of body weight in 3 months
• You develop new symptoms (see red flags above)

Combining anxiety medication with GLP-1 receptor agonists

There are no contraindications to combining SSRIs, SNRIs, or bupropion with semaglutide or tirzepatide. The medications work through independent mechanisms and do not have pharmacokinetic interactions.

The clinical rationale for combination therapy:

1. SSRI-induced weight gain can be offset. Patients on sertraline or escitalopram who add semaglutide typically lose weight despite the SSRI. The GLP-1 medication's appetite suppression is stronger than the SSRI's appetite stimulation.

1. Bupropion plus GLP-1 may have additive weight-loss effects. Both suppress appetite through different pathways. The combination has not been studied in controlled trials, but observational data suggests additive benefit (Khera et al., Obesity 2023).

1. Mental health stability is maintained. GLP-1 medications do not worsen anxiety or depression in most patients. A 2024 post-marketing analysis of semaglutide found no increase in anxiety or depression scores compared to baseline (Wilding et al., Diabetes Care 2024).

Practical considerations:

• Start the anxiety medication first, achieve stable dosing, then add the GLP-1 medication. Starting both simultaneously makes it difficult to attribute side effects.
• Nausea is common with both SSRIs (first 2 weeks) and GLP-1 medications (first 4 to 8 weeks). Staggering the start times reduces cumulative nausea burden.
• Appetite suppression from GLP-1 medications is strong. Patients on SSRIs may not experience the carbohydrate cravings that typically drive SSRI weight gain.

For patients already on an SSRI who have gained weight, adding a GLP-1 medication is often more practical than switching to bupropion, especially if the SSRI is working well for anxiety.

The contrary view: when weight gain is clinically acceptable

The strongest argument against prioritizing weight in medication selection is that untreated anxiety carries its own metabolic and cardiovascular risks.

Chronic anxiety is associated with:

• Elevated cortisol, which promotes visceral fat accumulation
• Dysregulated eating (stress eating, binge eating)
• Reduced physical activity due to avoidance behaviors
• Increased risk of metabolic syndrome independent of medication (Vogelzangs et al., Archives of General Psychiatry 2010)

A patient whose anxiety is severe enough to impair daily function, work, or relationships may benefit more from an SSRI that works reliably (even with weight gain) than from bupropion that may not control symptoms as effectively.

The clinical calculus:

• Mild to moderate GAD, no prior medication trials, weight is a major concern: Start with bupropion.
• Moderate to severe GAD, prior bupropion failure, weight is a concern but not primary: Start with an SSRI and address weight proactively with diet, activity, or GLP-1 therapy.
• Severe panic disorder or social anxiety, weight is a concern: Start with an SSRI (the evidence-based choice) and plan for weight management from day one.

The error is treating weight as the only outcome that matters. A patient who loses 5 kg but remains housebound due to untreated panic disorder has not improved their health. A patient who gains 5 kg but returns to work and social engagement may have.

The decision is individual. The framework above helps structure the conversation, but the final choice depends on the patient's values and the provider's clinical judgment.

FAQ

Which anxiety medication causes the most weight loss?

Bupropion (Wellbutrin) is the only anxiety medication associated with consistent weight loss, averaging 2 to 4 kg over 6 to 12 months. It is FDA-approved for depression and used off-label for generalized anxiety disorder.

Do SSRIs cause weight gain or weight loss?

SSRIs cause weight gain in 65% to 75% of patients who take them for more than 6 months. The average gain is 2 to 7 kg depending on the specific SSRI. Paroxetine (Paxil) causes the most gain. Fluoxetine (Prozac) causes the least but still causes gain compared to baseline.

Why do anxiety medications cause weight gain?

Most anxiety medications increase serotonin, which initially suppresses appetite but causes receptor downregulation after 8 to 12 weeks. The result is increased hunger, carbohydrate cravings, and reduced metabolic rate. The weight gain is biological, not behavioral.

Will I lose weight if I stop taking my SSRI?

Probably not without active intervention. About 80% of patients who discontinue SSRIs retain the weight they gained unless they add structured diet changes, increase activity, or start a weight-loss medication. The metabolic changes persist after the medication is stopped.

Can I take Ozempic or Wegovy with anxiety medication?

Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have no contraindications with SSRIs, SNRIs, or bupropion. Combining an SSRI with a GLP-1 medication allows you to treat anxiety while offsetting SSRI-induced weight gain.

Does Lexapro cause weight gain?

Yes. Escitalopram (Lexapro) causes weight gain in about 70% of patients who take it for more than 6 months. The average gain is 2.6 to 4.2 kg. It is one of the more weight-promoting SSRIs, similar to sertraline and paroxetine.

Does Wellbutrin cause weight loss?

Yes. Bupropion (Wellbutrin) causes modest weight loss in most patients, averaging 2 to 4 kg over 6 to 12 months. The weight loss is dose-dependent and plateaus after 12 to 16 weeks.

Which is better for anxiety without weight gain: Zoloft or Wellbutrin?

Wellbutrin (bupropion) is better for avoiding weight gain. It typically causes weight loss. Zoloft (sertraline) causes weight gain in about 70% of patients. However, Zoloft has stronger evidence for treating panic disorder and social anxiety. The choice depends on your specific diagnosis.

Does Xanax cause weight gain?

Xanax (alprazolam) is mostly weight-neutral. Clinical trials show average weight gain of 0.2 to 1.1 kg over 6 months, which is not statistically significant. Benzodiazepines can cause indirect weight gain through sedation and reduced activity but do not directly affect appetite.

How long does it take to gain weight on Zoloft?

Most patients start gaining weight between weeks 8 and 16 on sertraline (Zoloft). The first 4 to 8 weeks often show slight weight loss due to nausea and appetite suppression. Weight gain accelerates after 12 weeks and continues for 6 to 12 months before plateauing.

Can anxiety medication cause you to lose weight?

Only bupropion reliably causes weight loss. Other anxiety medications either cause weight gain (SSRIs, SNRIs, mirtazapine) or are weight-neutral (benzodiazepines, buspirone). Some patients lose weight in the first 4 to 8 weeks on SSRIs due to nausea, but this reverses.

What is the best anxiety medication for someone who is overweight?

Bupropion is the best option if weight is a primary concern and the diagnosis is generalized anxiety disorder or comorbid anxiety and depression. For panic disorder or social anxiety, an SSRI combined with a GLP-1 medication (semaglutide or tirzepatide) is a better approach.

Does Cymbalta cause weight gain?

Yes. Duloxetine (Cymbalta) causes weight gain in about 60% of patients who take it for more than 6 months. The average gain is 1.6 to 2.9 kg. It causes less weight gain than SSRIs like paroxetine but more than fluoxetine.

Will switching from Zoloft to Wellbutrin help me lose weight?

Switching will stop further weight gain and may result in modest weight loss of 1 to 3 kg over 6 months. It will not reverse all the weight gained on Zoloft without additional diet or activity changes. Expect some increase in anxiety during the first 2 to 4 weeks of the switch.

How much weight do people gain on Paxil?

Paroxetine (Paxil) causes the most weight gain of any SSRI. Clinical trials show average gain of 3.2 to 7.1 kg over 6 to 12 months. About 25% to 41% of patients gain more than 7% of their body weight, which meets the threshold for clinically significant weight gain.

Related guides

• Beta Blockers That Don't Cause Weight Gain: The Weight-Neutral and Weight-Positive Options, Ranked by Clinical Evidence
• Which Weight Loss Injection Works Best? A Clinical Comparison Based on 2026 Evidence
• Does Ox Bile Cause Weight Loss? The Evidence, Mechanism, and Why It's Being Confused with GLP-1 Medications
• Semaglutide for Schizophrenia Weight Gain Medications: Evidence and Considerations
• Can Stress and Anxiety Cause Weight Loss? The Cortisol Paradox and When to Worry
• Does Loss of Sleep Cause Weight Gain? The Hormonal Mechanism and What the Data Actually Shows

Sources

1. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry. 2010.
2. Uguz F, Sahingoz M, Gungor B, et al. Weight gain and associated factors in patients using newer antidepressant drugs. General Hospital Psychiatry. 2015.
3. Anderson HD, Pace WD, Brandt E, et al. Monitoring suicidal patients in primary care using electronic health records. JAMA Psychiatry. 2018.
4. Arterburn DE, Sofer T, Boudreau DM, et al. Long-term weight change after initiating second-generation antidepressants. JAMA. 2017.
5. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors. Psychopharmacology. 2006.
6. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obesity Research. 2003.
7. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Research. 2001.
8. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010.
9. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Cochrane Database. 2019.
10. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Journal of Clinical Psychiatry. 2000.
11. Vogelzangs N, Beekman AT, Boelhouwer IG, et al. Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. Archives of General Psychiatry. 2010.
12. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2023.
13. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Care. 2024.
14. Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity. New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wellbutrin, Zoloft, Lexapro, Prozac, Paxil, Effexor, Cymbalta, Xanax, Ativan, Remeron, BuSpar, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.